Clinical trials: Tace
Carcinoma, Hepatocellular
TACE Combined With Lenvatinib for Unresectable Hepatocellular Carcinoma (Prolong)
This is a multicenter, prospective, observational study in which subjects will be treated with lenvatinib combined with TACE in un-resectable HCC patients who had not received systematic treatment or TACE treatment in the past.
- Trial name
- NCT04560751
- Testing
- Lenvatinib, TACE
- Volunteers
- 300 people
- Sponsor
- Zhejiang Cancer Hospital
Hepatocellular Carcinoma
TACE Combined With Tyrosine Kinase Inhibitors and Tislelizumab in Unresectable Hepatocellular Carcinoma
Most hepatocellular carcinoma (HCC) are found in the intermediate or advanced stage. The patients lose the opportunity of curative surgical resection.
- Trial name
- NCT06232759
- Testing
- Transarterial chemoembolization combined with Tyrosine Kinase Inhibitors and Tislelizumab
- Where
- China
- Volunteers
- 56 people
- Sponsor
- Guangxi Medical University
Melanoma Neuroendocrine Tumors Neuroectodermal Tumors Neoplasms Germ Cell and Embryonal Neoplasms by Histologic Type Neoplasms Neoplasms
A Study of HX008 Plus Transcatheter Arterial Chemoembolization (TACE) in the First-Line Treatment of Subjects With Stage IV (M1c) Melanoma That is Metastatic to the Liver
The main purpose of this study is to compare the clinical benefit, as measured by Progression-Free Survival (PFS) and Overall Survival(OS), achieved by HX008 Plus Transcatheter Arterial Chemoembolization (TACE) or Temozolomide…
- Trial name
- NCT05647954
- Testing
- HX008 + TACE, Temozolomide + TACE, Pembrolizumab
- Where
- China
- Volunteers
- 350 people
- Sponsor
- Taizhou Hanzhong biomedical co. LTD
Hepatocellular Carcinoma, Portal Vein Thrombosis
Neo-TACE-HAIC for PVTT-HCC
Hepatocellular carcinoma (HCC) patients is a common disease in the East Asia. During the disease course, 20%-50% patients suffered portal vein tumor thrombus (PVTT), which is characterized with poor outcome and low response for…
- Trial name
- NeoconceptC (NCT04181931)
- Testing
- neo-TACE-HAIC+Surgery, Surgery alone
- Where
- 2 sites in China
- Volunteers
- 320 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma Non-resectable
Lenvatinib Plus DEB-TACE and HAIC vs. Lenvatinib Plus DEB-TACE for Large HCC With PVTT
This study is conducted to evaluate the efficacy and safety of lenvatinib plus transarterial chemoembolization (TACE) with drug-eluting beads (DEB-TACE) and hepatic artery infusion chemotherapy (HAIC) with FOLFOX regemen…
- Trial name
- NCT06492395
- Testing
- Len+DEB-TACE+HAIC, Len+DEB-TACE
- Where
- China
- Volunteers
- 178 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Carcinoma, Hepatocellular
Safety and Efficacy of Arsenic Trioxide Contained in TACE in the Treatment of HCC
The purpose of the study is to determine whether transarterial chemoembolization containing arsenic trioxide is safe and effective in the treatment of intermediate-stage hepatocellular carcinoma.
- Trial name
- SEATH (NCT02018757)
- Testing
- TACE containing As2O3
- Where
- 5 sites in China
- Volunteers
- 250 people
- Sponsor
- First Hospital of China Medical University
Hepatocellular Carcinoma Non-resectable
Fecal Microbiota Transplantation in Reversing Drug Resistance in Unresectable HCC (TALENP004)
This study aims to evaluate the safety and efficacy of fecal microbiota transplantation (FMT) in reversing drug resistance to the triple therapy regimen in patients with unresectable hepatocellular carcinoma (HCC).
- Trial name
- NCT06643533
- Testing
- Fecal Microbiota Transplantation
- Volunteers
- 15 people
- Sponsor
- Fujian Provincial Hospital
Hepatocellular Carcinoma
TACE With Dicycloplatin(TP21) in Unresectable HCC
To evaluate the effectiveness and safety of TP21 injection for TACE in treatment of hepatocellular carcinoma: 1. Primary efficacy endpoint: progression-free survival (PFS), which will be assessed by the Independent Review…
- Trial name
- NCT05472896
- Testing
- cTACE, Dicycloplatin (TP21), Epirubicin
- Where
- China
- Volunteers
- 332 people
- Sponsor
- Gao-jun Teng
Unresectable Colorectal Cancer, Advanced Malignancy
Clinical Efficacy of Transarterial Chemoembolization in Elderly Patients With Advanced Unresectable Colorectal Cancer
We plan to conduct a prospective, two-arm, open-label phase Ⅱ study to evaluate whether transarterial chemoembolization with FOLFOX plus/minus intravenous cetuximab/bevacizumab significantly improves the efficacy and safety…
- Conditions
- Unresectable Colorectal Cancer, Advanced Malignancy, Elderly (People Aged 65 or More)
- Trial name
- NCT07209384
- Testing
- Transarterial chemoembolization
- Volunteers
- 50 people
- Sponsor
- Junpeng Wang
Unresectable Hepatocellular Carcinoma, Undergoing Chemoembolization and Radioembolization
TACE Study-Liver Embolization Perfusion (VGH Radiology LIU)
The purpose of this research study is to evaluate the quantitative information of utilizing C-arm systems in liver tumor care in hopes this potential clinical combination of imaging could aid in diagnosis and evaluation of tumor…
- Trial name
- TACE (NCT02093104)
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- University of British Columbia
Hepatocellular Carcinoma Non-resectable, Conversion
Non-inferiority Study of Unresectable Hepatocelluar Carcinoma Receiving Stereotactic Radiotherapy Combined With Hepatic Arterial Chemoembolization Compared With Conversion Hepatectomy
To compare the prognosis and adverse reactions of unresectable hepatocellular carcinoma receiving stereotactic radiotherapy combined with hepatic arterial chemoembolization and conversion hepatectomy
- Trial name
- NCT05057104
- Volunteers
- 320 people
- Sponsor
- Beijing 302 Hospital
Hepatocellular Carcinoma
AI-Based Multimodal Integration for Tumor Microenvironment Analysis and Response Prediction in HCC Treated With TACE Plus Immunotherapy and Targeted Therapy (CHANCE2601)
This study aims to prospectively validate a retrospective cohort-derived AI-based multimodal model and explore tumor heterogeneity and the immune microenvironment to guide TACE combined with immunotherapy and targeted therapy in…
- Trial name
- NCT07584317
- Testing
- Artificial Intelligence
- Volunteers
- 1,170 people
- Sponsor
- Gao-jun Teng
Postoperative Adjuvant TACE, Hepatocellular Carcinoma.
Postoperative Adjuvant TACE Treatment in CK18 Positive Patients
To evaluate and analyse the clinical effect and application value of postoperative adjuvant TACE treatment in patients with different expression levels of CK18 using randomized controlled study and provide evidence for the…
- Trial name
- NCT02724345
- Where
- China
- Volunteers
- 320 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Unresectable Hepatocellular Carcinoma, Transarterial Chemoembolization
TACE Plus Camrelizumab and Apatinib for Unresectable Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the sixth most common cancer and the third most common cause of cancer-related death worldwide.
- Conditions
- Unresectable Hepatocellular Carcinoma, Transarterial Chemoembolization, Camrelizumab, Apatinib
- Trial name
- NCT06485466
- Testing
- TACE plus camrelizumab and apatinib, Camrelizumab and apatinib
- Where
- China
- Volunteers
- 101 people
- Sponsor
- Guohui Xu
Hepatocellular Carcinoma (HCC), Unresectable Hepatocellular Cancer
GKL-006 Injection Plus TACE Versus TACE Alone in Patients With Unresectable Hepatocellular Carcinoma
This is a multicenter, randomized, open-label, controlled Phase 2 study in patients with unresectable hepatocellular carcinoma (uHCC).
- Trial name
- NCT07209813
- Testing
- GKL-006 Injection, TACE
- Where
- 7 sites in China
- Volunteers
- 48 people
- Sponsor
- Beijing Gene Key Life Technology Co., Ltd
Hepatocellular Carcinoma
Efficacy and Safety of TACE on Downstaging Hepatocellular Carcinoma Beyond UCSF Criteria;
This is a multicenter, randomized, parallel controlled study to determine the efficacy and safety of transcatheter arterial chemoembolization (TACE) on downstaging hepatocellular carcinoma beyond University of California, San…
- Trial name
- NCT04738188
- Testing
- DEB-TACE, cTACE, Drug-eluting Beads
- Where
- China
- Volunteers
- 226 people
- Sponsor
- Beijing Tsinghua Chang Gung Hospital
Primary Hepatocellular Carcinoma
Clinical Trial of Radiotherapy in Treating Primary Hepatocellular Carcinoma
The subjects of primary hepatocellular carcinoma diagnosed pathologically or clinically will be grouped according to the size, location, number and function of the liver, and respectively received Intensity-modulated Radiation…
- Trial name
- NCT03614546
- Testing
- SBRT, IMRT, Hepatectomy
- Where
- China
- Volunteers
- 200 people
- Sponsor
- The Third Xiangya Hospital of Central South University
Pain Control, Liver Cancer
Hepatic Hilar Nerve Block Versus Sham in Pain Control During Liver Ablation and TACE Procedures
This study is aimed at assessing the effectiveness of a novel liver specific nerve block in improving pain control during painful liver interventional radiology procedures including liver tumoral ablation and trans arterial…
- Trial name
- NCT04769713
- Testing
- Hepatic Hilar Nerve Block Needle placement, Injection of Ropivacaine in the hepatic hilum for the hepatic hilar nerve block
- Where
- Canada
- Volunteers
- 80 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Hepatocellular Carcinoma
Evaluation the Treatment Outcome for RFA in Patients With BCLC Stage B HCC in Comparison With TACE
Evaluation the Treatment Outcome for RFA in Patients With BCLC Stage B HCC in Comparison With TACE
- Trial name
- NCT03642561
- Testing
- radiotherapy ablation, transarterial chemoembolization(TACE)
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Fudan University
Hepatocellular Carcinoma (HCC) With Type III Portal Vein Tumor Thrombus (PVTT)
Safety and Efficacy of GSMs-TACE Combined With Surgical Resection in the Treatment of Hepatocellular Carcinoma (HCC) With Type III Portal Vein Tumor Thrombus (PVTT)
A Single center, Open, Randomized Controlled Trial Evaluating the Safety and Efficacy of GSMs-TACE Combined with Surgical Resection in the Treatment of Hepatocellular Carcinoma (HCC) with Type III Portal Vein Tumor Thrombus…
- Trial name
- NCT04619342
- Testing
- GSMs-TACE, Surgical Resection
- Where
- China
- Volunteers
- 98 people
- Sponsor
- Beijing Tsinghua Chang Gung Hospital